4543 On Other Exchanges
Symbol
Exchange
4543 is not on other exchanges.

terumo corp (4543) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TERUMO CORP (4543)

Related News

No related news articles were found.

terumo corp (4543) Related Businessweek News

No Related Businessweek News Found

terumo corp (4543) Details

Terumo Corporation manufactures and sells medical devices and pharmaceuticals worldwide. It provides products in the areas of cardiovascular, hospital, and blood systems. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro catheters and guide wires, micro balloon catheters, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and devices for percutaneous cardiopulmonary support system; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems, including infusion pumps, closed infusion systems, and IV catheters; closed anticancer drug infusion systems; drugs and devices comprising prefilled syringes and pre-fillable syringes; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices. Further, it provides analgesic and antiemetic pain management drugs; diabetes management devices; measuring device systems, such as blood glucose and blood pressure monitors, thermometers, pulse oximeters, and walking intensity and body composition monitors; and basal thermometers, fall prevention products, oral care products, urine test strips, and deodorizing devices. Additionally, the company offers automated blood collection and blood component processing systems, blood bag system with leukocyte reduction filters, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

20,697 Employees
Last Reported Date: 06/27/16
Founded in 1921

terumo corp (4543) Top Compensated Officers

Senior Executive Officer, Director, Chief Exe...
Total Annual Compensation: ¥168.0M
Compensation as of Fiscal Year 2016.

terumo corp (4543) Key Developments

Terumo Corporation Provides Dividend Guidance for the Second Quarter of 2017; Provides Dividend Guidance for the Fourth Quarter Ending March 31, 2017

Terumo Corporation provided dividend guidance for the second quarter of 2017. For the quarter, the company expects to pay dividend of ¥20.00 per share against ¥19.00 per share a year ago. For the fourth quarter ending March 31, 2017, the company expects to pay dividend of ¥21.00 per share against ¥20.00 per share a year ago.

Terumo Corporation Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Earnings Guidance for the Half Year and Full Year of Fiscal 2017

Terumo Corporation reported consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company's net sales were JPY 124,519 million against JPY 128,660 million a year ago. Operating income JPY 21,356 million against JPY 19,449 million a year ago. Ordinary income JPY 15,123 million against JPY 20,592 million a year ago. Profit attributable to owners of parent JPY 10,110 million or JPY 25.99 per diluted share against JPY 14,504 million or JPY 35.83 per diluted share a year ago. Income before income taxes was JPY 15,079 million against JPY 20,632 million a year ago. The company provided earnings guidance for the half year and full year of fiscal 2017. For the half year ending September 2016, the company expects net sales of JPY 250,000 million, operating income of JPY 35,500 million, ordinary income of JPY 32,500 million and profit attributable to owners of parent of JPY 21,500 million or JPY 59.23 per share. For the year ending March 2017, the company expects net sales of JPY 517,000 million, operating income of JPY 75,000 million, ordinary income of JPY 71,000 million and profit attributable to owners of parent of JPY 52,500 million or JPY 114.64 per share.

Terumo Corporation to Report Q1, 2017 Results on Aug 04, 2016

Terumo Corporation announced that they will report Q1, 2017 results at 8:00 AM, Coordinated Universal Time on Aug 04, 2016

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4543 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4543.
View Industry Companies
 

Industry Analysis

4543

Industry Average

Valuation 4543 Industry Range
Price/Earnings 37.6x
Price/Sales 3.1x
Price/Book 3.4x
Price/Cash Flow 36.0x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TERUMO CORP, please visit www.terumo.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.